Cathepsin L targeting in cancer treatment

Dhivya R. Sudhan, Dietmar W. Siemann

Research output: Contribution to journalReview articlepeer-review

110 Scopus citations


Proteolytic enzymes may serve as promising targets for novel therapeutic treatment strategies seeking to impede cancer progression and metastasis. One such enzyme is cathepsin L (CTSL), a lysosomal cysteine protease. CTSL upregulation, a common occurrence in a variety of human cancers, has been widely correlated with metastatic aggressiveness and poor patient prognosis. In addition, CTSL has been implicated to contribute to cancer-associated osteolysis, a debilitating morbidity affecting both life expectancy and the quality of life. In this review, we highlight the mechanisms by which CTSL contributes to tumor progression and dissemination and discuss the therapeutic utility of CTSL intervention strategies aimed at impeding metastatic progression and bone resorption.

Original languageEnglish (US)
Pages (from-to)105-116
Number of pages12
JournalPharmacology and Therapeutics
StatePublished - Nov 2015
Externally publishedYes


  • Bone resorption
  • Cancer
  • Cathepsin L
  • Metastasis
  • Protease targeting

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Cathepsin L targeting in cancer treatment'. Together they form a unique fingerprint.

Cite this